Diabetes, obesity, and erectile dysfunction

Gender Medicine

Volumn 6, Issue SUPPL. 1, 2009, Pages 4-16

  Tamler, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

coronary artery disease; diabetes; endothelial dysfunction; erectile dysfunction; hypogonadism; obesity

Indexed keywords

C REACTIVE PROTEIN; CYCLIC GMP; ENDOTHELIN 1; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPOGONADISM; MALE; MEDICAL LITERATURE; MEDLINE; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; ENDOTHELIUM; ERECTILE DYSFUNCTION; HUMANS; HYPOGONADISM; MALE; OBESITY; PREVALENCE; RISK FACTORS; TESTOSTERONE; UNITED STATES;

EID: 62649124818     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genm.2008.12.003     Document Type: Article

References (145)

1. Hedley A.A., Ogden C.L., Johnson C.L., et al. Prevalence of overweight and obesity among US children, adolescents and adults, 1999-2002. JAMA 291 (2004) 2847-2850
2. Kelly T., Yang W., Chen C.S., and Reynolds K. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 32 (2008) 1431-1437
3. Haslam D.W., and James W.P. Obesity. Lancet 366 (2005) 1197-1209
4. Hu F.B., Manson J.E., Stampfer M.J., et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345 (2001) 790-797
5. Franco O.H., Steyerberg E.W., Hu F.B., et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 167 (2007) 1145-1151
6. Grundy S.M., Cleeman J.I., Bairey Merz C.N., et al., for the Coordinating Committee of the National Cholesterol Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
7. Austad S.N. Why women live longer than men: Sex differences in longevity. Gend Med 3 (2006) 79-92
8. Tamler R. Preface. Endocrinol Metab Clinics North Am 36 (2007) 107-108
9. Lue T.F., Giuliano F., Montorsi F., et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 1 (2004) 6-23
10. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 151 (1994) 54-61
11. Derby C.A., Mohr B.A., Goldstein I., et al. Modifiable risk factors and erectile dysfunction: Can lifestyle changes modify risk?. Urology 56 (2000) 302-306
12. Shabsigh R., Perelman M.A., Lockhart D.C., et al. Health issues of men: Prevalence and correlates of erectile dysfunction. J Urol 174 (2005) 662-667
13. Heidler S., Temml C., Broessner C., et al. Is the metabolic syndrome an independent risk factor for erectile dysfunction?. J Urol 177 (2007) 651-654
14. Nikoobakht M., Nasseh H., and Pourkasmaee M. The relationship between lipid profile and erectile dysfunction [published retraction appears in Int J Impot Res. 2007;19:617]. Int J Impot Res 17 (2005) 523-526
15. Burke J.P., Jacobson D.J., McGree M.E., et al. Diabetes and sexual dysfunction: Results from the Olmsted County study of urinary symptoms and health status among men. J Urol 177 (2007) 1438-1442
16. Riedner C.E., Rhoden E.L., Ribeiro E.P., and Fuchs S.C. Central obesity is an independent predictor of erectile dysfunction in older men. J Urol 176 (2006) 1519-1523
17. EI-Sakka A.I. Association of risk factors and medical comorbidities with male sexual dysfunctions. J Sex Med 4 (2007) 1691-1700
18. He J., Reynolds K., Chen J., et al. Cigarette smoking and erectile dysfunction among Chinese men without clinical vascular disease. Am J Epidemiol 166 (2007) 803-809
19. Ponholzer A., Temml C., Mock K., et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 47 (2005) 80-85
20. Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later (the Rancho Bernardo Study). Am J Cardiol 96 (2005) 3M-7M
21. Saigal C.S., Wessells H., Pace J., et al., for the Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 166 (2006) 207-212
22. Fonseca V., and Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: Common pathways and treatments?. Am J Cardiol 96 (2005) 13M-18M
23. Vinik A., and Richardson D. Erectile dysfunction in diabetes. Diabetes Rev 6 (1998) 16-33
24. Fedele D., Coscelli C., Santeusanio F., et al., for the Gruppo Italiano Studio Deficit Erettile nei Diabetici. Erectile dysfunction in diabetic subjects in Italy. Diabetes Care 21 (1998) 1973-1977
25. Braun M., Wassmer G., Klotz T., et al. Epidemiology of erectile dysfunction: Results of the 'Cologne Male Survey'. Int J Impot Res 12 (2000) 305-311
26. Bacon C.G., Hu F.B., Giovannucci E., et al. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 25 (2002) 1458-1463
27. Rhoden E.L., Ribeiro E.P., Riedner C.E., et al. Glycosylated haemoglobin levels and the severity of erectile function in diabetic men. BJU Int 95 (2005) 615-617
28. Klein R., Klein B.E., Lee K.E., et al. Prevalence of self-reported erectile dysfunction in people with longterm IDDM. Diabetes Care 19 (1996) 135-141
29. Romeo J.H., Seftel A.D., Madhun Z.T., and Aron D.C. Sexual function in men with diabetes type 2: Association with glycemic control. J Urol 163 (2000) 788-791
30. Bhatt D.L., Steg P.G., Ohman E.M., et al., for the REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189
31. Thompson I.M., Tangen C.M., Goodman P.J., et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 294 (2005) 2996-3002
32. Vlachopoulos C., Rokkas K., Ioakeimidis N., et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: A prospective angiographic study. Eur Urol 48 (2005) 996-1002
33. Borgquist R., Nilsson P.M., Gudmundsson P., et al. Coronary flow velocity reserve reduction is comparable in patients with erectile dysfunction and in patients with impaired fasting glucose or well-regulated diabetes mellitus. Eur J Cardiovasc Prev Rehabil 14 (2007) 258-264
34. Borgquist R., Gudmundsson P., Winter R., et al. Erectile dysfunction in healthy subjects predicts reduced coronary flow velocity reserve. Int J Cardiol 112 (2006) 166-170
35. Blumentals W.A., Gomez-Caminero A., Joo S., and Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res 16 (2004) 350-353
36. Gazzaruso C., Giordanetti S., De Amici E., et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncom plicated type 2 diabetic patients. Circulation 110 (2004) 22-26
37. Gazzaruso C., Pujia A., Solerte S.B., et al. Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. Int J Impot Res 18 (2006) 311-315
38. Gazzaruso C., Solerte S.B., Pujia A., et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: A potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 51 (2008) 2040-2044
39. Ma R.C., So W.Y., Yang X., et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 51 (2008) 2045-2050
40. Montorsi F., Briganti A., Salonia A., et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 44 (2003) 360-364
41. Montorsi P., Ravagnani P.M., Galli S., et al. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol 50 (2006) 721-731
42. Montorsi P., Montorsi F., and Schulman C.C. Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder?. Eur Urol 44 (2003) 352-354
43. Tamler R., and Bar-Chama N. Assessment of endothelial function in the patient with erectile dysfunction: An opportunity for the urologist. Int J Impot Res 20 (2008) 370-377
44. Solomon H., Man J.W., Wierzbicki A.S., and Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol 91 (2003) 230-231
45. Montorsi P., Ravagnani P.M., Galli S., et al. The artery size hypothesis: A macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 96 (2005) 19M-23M
46. Guay A.T. ED2: Erectile dysfunction = endothelial dysfunction. Endocrinol Metab Clin North Am 36 (2007) 453-463
47. Billups K.L., Bank A.J., Padma-Nathan H., et al. Erectile dysfunction is a marker for cardiovascular disease: Results of the minority health institute expert advisory panel. J Sex Med 2 (2005) 40-50
48. Seftel A.D., Vaziri N.D., Ni Z., et al. Advanced glycation end products in human penis: Elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 50 (1997) 1016-1026
49. Cooke J.P. The endothelium: A new target for therapy. Vasc Med 5 (2000) 49-53
50. Lekakis J., Papamichael C., Vemmos C., et al. Effects of acute cigarette smoking on endothelium-dependent arterial dilatation in normal subjects. Am J Cardiol 81 (1998) 1225-1228
51. Higashi Y., Sasaki S., Nakagawa K., et al. Effect of obesity on endothelium-dependent, nitric oxidemediated vasodilation in normotensive individuals and patients with essential hypertension. Am J Hypertens 14 (2001) 1038-1045
52. Kaiser D.R., Billups K., Mason C., et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 43 (2004) 179-184
53. Steinberg H.O., Paradisi G., Cronin J., et al. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 101 (2000) 2040-2046
54. Steinberg H.O., and Baron A.D. Vascular function, insulin resistance and fatty acids. Diabetologia 45 (2002) 623-634
55. Brook R.D. Obesity, weight loss, and vascular function. Endocrine 29 (2006) 21-25
56. Brook R.D., Bard R.L., Rubenfire M., et al. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 88 (2001) 1264-1269
57. Petrie J.R., Ueda S., Webb D.J., et al. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation 93 (1996) 1331-1333
58. Kedzierski R.M., and Yanagisawa M. Endothelin system: The double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41 (2001) 851-876
59. Yanagisawa M., Kurihara H., Kimura S., et al. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl 6 (1988) S188-S191
60. Ito H., Hirata Y., Adachi S., et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 92 (1993) 398-403
61. Ehrenreich H., Anderson R.W., Fox C.H., et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 172 (1990) 1741-1748
62. Böhm F., and Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 76 (2007) 8-18
63. Segura J., and Ruilope L.M. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr 10 (2007) 1151-1155
64. Yamagishi S., Ueda S., Nakamura K., et al. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des 25 (2008) 2613-2618
65. Palmer R.M., Ferrige A.G., and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987) 524-526
66. Juonala M., Viikari J.S., Alfthan G., et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 116 (2007) 1367-1373
67. Ardigo D., Stüehlinger M., Franzini L., et al. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest 37 (2007) 263-269
68. Valkonen V.P., Päivä H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
69. Mittermayer F., Krzyzanowska K., Exner M., et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 26 (2006) 2536-2540
70. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene Study. Circ Res 97 (2005) e53-e59
71. Elesber A.A., Solomon H., Lennon R.J., et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 27 (2006) 824-831
72. Maas R., Wenske S., Zabel M., et al. Elevation of asymmetrical dimethylarginine (ADMA) and coronary artery disease in men with erectile dysfunction. Euro Urol 48 (2005) 1004-1011
73. Nawawi H., Osman N.S., Annuar R., et al. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 169 (2003) 283-291
74. Naya M., Tsukamoto T., Morita K., et al. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res 30 (2007) 541-548
75. Silvestro A., Brevetti G., Schiano V., et al. Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification. Thromb Haemost 93 (2005) 559-563
76. Vlachopoulos C., Aznaouridis K., loakeimidis N., et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J 27 (2006) 2640-2648
77. Giugliano F., Esposito K., Di Palo C., et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest 27 (2004) 665-669
78. Kojda G., and Harrison D. Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 43 (1999) 562-571
79. Kuzkaya N., Weissmann N., Harrison D.G., and Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: Implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 278 (2003) 22546-22554
80. Cooke J.P. Asymmetrical dimethylarginine: The uber marker?. Circulation 109 (2004) 1813-1818
81. Koppenol W.H., Moreno J.J., Pryor W.A., et al. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem Res Toxicol 5 (1992) 834-842
82. Jiaan D.B., Seftel A.D., Fogarty J., et al. Age-related increase in an advanced glycation end product in penile tissue. World J Urol 13 (1995) 369-375
83. Steinberg H.O., Tarshoby M., Monestel R., et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100 (1997) 1230-1239
84. Lin Y., Weisdorf D.J., Solovey A., and Hebbel R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105 (2000) 71-77
85. Reyes M., Dudek A., Jahagirdar B., et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 109 (2002) 337-346
86. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
87. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85 (1999) 221-228
88. Eguchi M., Masuda H., and Asahara T. Endothelial progenitor cells for postnatal vasculogenesis. Clin Exp Nephrol 11 (2007) 18-25
89. Masuda H., Kalka C., and Asahara T. Endothelial progenitor cells for regeneration. Hum Cell 13 (2000) 153-160
90. Foresta C., Caretta N., Lana A., et al. Circulating endothelial progenitor cells in subjects with erectile dysfunction. Int J Impot Res 17 (2005) 288-290
91. Baumhäkel M., Werner N., Böhm M., and Nickenig G. Circulating endothelial progenitor cells correlate with erectile function in patients with coronary heart disease. Eur Heart J 27 (2006) 2184-2188
92. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
93. Mutin M., Canavy I., Blann A., et al. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 93 (1999) 2951-2958
94. Bemelmans B.L., Meuleman E.J., Doesburg W.H., et al. Erectile dysfunction in diabetic men: The neurological factor revisited. J Urol 151 (1994) 884-889
95. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2006;91:2688]. J Clin Endocrinol Metab 91 (2006) 1995-2010
96. Cunningham G.R. Testosterone replacement therapy for late-onset hypogonadism. Nat Clin Pract Urol 3 (2006) 260-267
97. Dhindsa S., Prabhakar S., Sethi M., et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 5462-5468
98. Svartberg J., von Mühlen D., Sundsfjord J., and Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromsø study. Eur J Epidemiol 19 (2004) 657-663
99. Dunajska K., Milewicz A., Szymczak J., et al. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. Aging Male 7 (2004) 197-204
100. Deslypere J.P., Verdonck L., and Vermeulen A. Fat tissue: A steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab 61 (1985) 564-570
101. Gennari L., Masi L., Merlotti D., et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: Effects on bone metabolism. J Clin Endocrinol Metab 89 (2004) 2803-2810
102. Hayes F.J., Seminara S.B., Decruz S., et al. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 85 (2000) 3027-3035
103. de Boer H., Verschoor L., Ruinemans-Koerts J., and Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes Obes Metab 7 (2005) 211-215
104. Tripathy D., Dhindsa S., Garg R., et al. Hypogonadotropic hypogonadism in erectile dysfunction associated with type 2 diabetes mellitus: A common defect?. Metab Syndr Relat Disord 1 (2003) 75-80
105. Svartberg J., Jenssen T., Sundsfjord J., and Jorde R. The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromsø Study. Diabetes Metab 30 (2004) 29-34
106. Muller M., Grobbee D.E., den Tonkelaar I., et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 90 (2005) 2618-2623
107. Kupelian V., Page S.T., Araujo A.B., et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91 (2006) 843-850
108. Ding E.L., Song Y., Malik V.S., and Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 295 (2006) 1288-1299
109. Braga-Basaria M., Muller D.C., Carducci M.A., et al. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 18 (2006) 494-498
110. Basaria S., Muller D.C., Carducci M.A., et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106 (2006) 581-588
111. Swerdlow A.J., Higgins C.D., Schoemaker M.J., et al., for the United Kingdon Clinical Cytogenetics Group. Mortality in patients with Klinefelter syndrome in Britain: A cohort study. J Clin Endocrinol Metab 90 (2005) 6516-6522
112. Bojesen A., Juul S., Birkebaek N.H., and Gravholt C.H. Morbidity in Klinefelter syndrome: A Danish register study based on hospital discharge diagnoses. J Clin Endocrinol Metab 91 (2006) 1254-1260
113. Pedersen S.B. Studies on receptors and actions of steroid hormones in adipose tissue. Dan Med Bull 52 (2005) 258
114. Mårin P., Lönn L., Andersson B., et al. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: Effects of testosterone. J Clin Endocrinol Metab 81 (1996) 1018-1022
115. Mårin P., Odén B., and Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: Effects of androgens. J Clin Endocrinol Metab 80 (1995) 239-243
116. Mårin P., and Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab 12 (1998) 441-451
117. Rebuffé-Scrive M., Mårin P., and Björntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes 15 (1991) 791-795
118. Rondinone C.M. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 29 (2006) 81-90
119. Murdolo G., and Smith U. The dysregulated adipose tissue: A connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. Nutr Metab Cardiovasc Dis 16 Suppl 1 (2006) S35-S38
120. Ibrahim I.A., Kang E., and Dansky K.H. Polypharmacy and possible drug-drug interactions among diabetic patients receiving home health care services. Home Health Care Serv Q 24 (2005) 87-99
121. Shiri R., Koskimäki J., Häkkinen J., et al. Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 19 (2007) 208-212
122. Jackson G., Rosen R.C., Kloner R.A., and Kostis J.B. The second Princeton consensus on sexual dysfunction and cardiac risk: New guidelines for sexual medicine. J Sex Med 3 (2006) 28-36
123. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 96 (2005) 85M-93M
124. Smith N.J., Sak S.C., Baldo O., and Eardley I. The prevalence of newly diagnosed hyperlipidaemia in men with erectile dysfunction. BJU Int 100 (2007) 357-361
125. Lue T.F. Erectile dysfunction. N Engl J Med 342 (2000) 1802-1813
126. Goldstein I., Lue T.F., Padma-Nathan H., et al., for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. [published correction appears in N Engl J Med. 1998;339:59]. N Engl J Med 338 (1998) 1397-1404
127. Ballard S.A., Gingell C.J., Tang K., et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159 (1998) 2164-2171
128. Beavo J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75 (1995) 725-748
129. Sommer F., and Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol 23 (2005) 385-392
130. Koskimäki J., Shiri R., Tammela T., et al. Regular intercourse protects against erectile dysfunction: Tampere Aging Male Urologic Study. Am J Med 121 (2008) 592-596
131. Behr-Roussel D., Gorny D., Mevel K., et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: Lack of tachyphylaxis. Eur Urol 47 (2005) 87-91
132. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 1 (2004) 292-300
133. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2 (2005) 415-425
134. Foresta C., Lana A., Cabrelle A., et al. PDE-5 inhibitor, vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 17 (2005) 377-380
135. Foresta C., Ferlin A., De Toni L., et al. Circulating endothelial progenitor cells and endothelial function after chronic tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 18 (2006) 484-488
136. Bocchio M., Pelliccione F., Passacluale G., et al. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis 196 (2008) 313-319
137. Aversa A., Greco E., Bruzziches R., et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: A pilot study. Int J Impot Res 19 (2007) 200-207
138. Rosano G.M., Aversa A., Vitale C., et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47 (2005) 214-220
139. Aversa A., Bruzziches R., Vitale C., et al. Chronic sildenafil in men with diabetes and erectile dysfunction. Exp Opin Drug Metab Toxicol 3 (2007) 451-464
140. Aversa A., Vitale C., Volterrani M., et al. Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 25 (2008) 37-44
141. Mårin P., Holmäng S., Jönsson L., et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Discord 16 (1992) 991-997
142. Esposito K., Giugliano F., Di Palo C., et al. Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial. JAMA 291 (2004) 2978-2984
143. Esposito K., Ciotola M., Giugliano F., et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 18 (2006) 405-410
144. Horasanli K., Boylu U., Kendirci M., and Miroglu C. Do lifestyle changes work for improving erectile dysfunction?. Asian J Androl 10 (2008) 28-35
145. Pierce G.L., Beske S.D., Lawson B.R., et al. Weight loss alone improves conduit and resistance artery endothelial function in young and older overweight/obese adults. Hypertension 52 (2008) 72-79